RetinalGenix Technologies Inc. (RTGN)

USD 53.0

(88.0%)

Net Debt Summary of RetinalGenix Technologies Inc.

  • RetinalGenix Technologies Inc.'s latest annual net debt in 2023 was 506.53 Thousand USD , up 934.55% from previous year.
  • RetinalGenix Technologies Inc.'s latest quarterly net debt in 2024 Q2 was -37.91 Thousand USD , down -2635.43% from previous quarter.
  • RetinalGenix Technologies Inc. reported annual net debt of 48.96 Thousand USD in 2022, down -28.05% from previous year.
  • RetinalGenix Technologies Inc. reported annual net debt of 68.05 Thousand USD in 2021, up 3166.83% from previous year.
  • RetinalGenix Technologies Inc. reported quarterly net debt of -1386.00 USD for 2024 Q1, down -102.83% from previous quarter.
  • RetinalGenix Technologies Inc. reported quarterly net debt of 47.08 Thousand USD for 2023 Q2, up 13.38% from previous quarter.

Annual Net Debt Chart of RetinalGenix Technologies Inc. (2023 - 2018)

Historical Annual Net Debt of RetinalGenix Technologies Inc. (2023 - 2018)

Year Net Debt Net Debt Growth
2023 506.53 Thousand USD 934.55%
2022 48.96 Thousand USD -28.05%
2021 68.05 Thousand USD 3166.83%
2020 -2219.00 USD 95.92%
2019 -54.38 Thousand USD 0.0%
2018 - USD 0.0%

Peer Net Debt Comparison of RetinalGenix Technologies Inc.

Name Net Debt Net Debt Difference
Acutus Medical, Inc. 12.27 Million USD 95.875%
Biotricity, Inc. 23.09 Million USD 97.807%
Cell MedX Corp. 244.05 Thousand USD -107.553%
Dynatronics Corporation 6.2 Million USD 91.835%
Nemaura Medical Inc. 9.92 Million USD 94.896%
PetVivo Holdings, Inc. 1.27 Million USD 60.354%
Sonendo, Inc. 26.34 Million USD 98.077%
Telesis Bio, Inc. 32.63 Million USD 98.448%
Talis Biomedical Corporation -57.06 Million USD 100.888%
Viveve Medical, Inc. -13.81 Million USD 103.667%